Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis.

Sandra TorresCristina OrtizNadine BachtlerWenyi GuLeon D GrünewaldNico KrausRobert SchierwagenChristoph HieberCaroline MeierOlaf TycMaximilian Joseph BrolFrank Erhard UschnerBart NijmeijerChristoph WelschMarie-Luise BerresCarmen Garcia-RuizJose Carlos Fernandez-ChecaChristian TrautweinThomas J VoglStefan ZeuzemJonel TrebickaSabine Klein

Published in: Hepatology (Baltimore, Md.) (2022)

This study demonstrates that the JAK2 inhibitor pacritinib may be promising for the treatment of alcoholic and nonalcoholic liver fibrosis and may be therefore relevant for human pathology.

Keyphrases

liver fibrosis
endothelial cells
induced pluripotent stem cells
tyrosine kinase
combination therapy
protein kinase
pluripotent stem cells
risk assessment
human health
climate change